Merck & Co has linked up again with Bionomics, this time for Alzheimer’s disease, in a deal that could be worth over half a billion dollars to the Australian biotech. The collaboration centres around BNC375, a compound which has displayed … Continue reading
June 25, 2014
by PharmaReviews
0 comments